In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on BioLife Solutions (BLFS – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $18.01.
According to TipRanks, Flaten is an analyst with an average return of -9.6% and a 33.87% success rate. Flaten covers the Healthcare sector, focusing on stocks such as Optinose, Aquestive Therapeutics, and Achieve Life Sciences.
BioLife Solutions has an analyst consensus of Strong Buy, with a price target consensus of $23.60, implying a 31.04% upside from current levels. In a report released today, Northland Securities also maintained a Buy rating on the stock with a $26.00 price target.
BLFS market cap is currently $815.9M and has a P/E ratio of -12.62.
Based on the recent corporate insider activity of 170 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLFS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLife Solutions (BLFS) Company Description:
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
